Prostate-specific antigen: a misused and maligned prostate cancer biomarker
- PMID: 18957671
- PMCID: PMC2579315
- DOI: 10.1093/jnci/djn368
Prostate-specific antigen: a misused and maligned prostate cancer biomarker
Comment in
-
Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.J Natl Cancer Inst. 2009 Apr 15;101(8):611-2. doi: 10.1093/jnci/djp043. Epub 2009 Apr 7. J Natl Cancer Inst. 2009. PMID: 19351913 No abstract available.
Comment on
-
The influence of statin medications on prostate-specific antigen levels.J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8. doi: 10.1093/jnci/djn362. Epub 2008 Oct 28. J Natl Cancer Inst. 2008. PMID: 18957682
References
-
- Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294(1):66–70. - PubMed
-
- Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98(16):1128–1133. - PubMed
-
- Kristal AR, Chi C, Tangen CM, et al. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106(2):320–328. - PubMed
-
- Kristal AR, Gong Z. Obesity and prostate cancer mortality. Future Oncol. 2007;3(5):557–567. - PubMed
-
- Fleming TR, Demets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605–613. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical